Effect of physician-prescribed nalmefene on alcohol intake reduction in patients with alcohol-related liver disease

Research output: Contribution to journalArticlepeer-review

Abstract

A brief intervention is often effective for patients with mild alcohol use disorder (AUD), but it is not effective for most patients with severe AUD or alcohol dependence to reduce alcohol intake. Nalmefene (Selincro®), an opioid receptor modulator, was approved in Japan in 2019. Nalmefene was administered to 18 outpatients with alcohol-related liver diseases. Five patients stopped coming to the hospital without notice, and two patients stopped taking medicine due to dizziness. Thus, 11 patients were noted to have reduced amount of alcohol intake at 24 weeks of using nalmefene. However, one of these patients was referred to a hospital specializing in alcohol dependence thereafter. Thus, the use of nalmefene provides a new concept for AUD treatment (i. e., alcohol intake reduction). However, some adverse events are noted, such as nausea and dizziness. Therefore, physicians with more experience with AUD treatment should use the drugma.

Original languageEnglish
Pages (from-to)620-629
Number of pages10
JournalActa Hepatologica Japonica
Volume62
Issue number10
DOIs
Publication statusPublished - 2021

Keywords

  • Alcohol dependence
  • Alcohol-related liver disease
  • Harm reduction
  • Nalmefene
  • Serincro

ASJC Scopus subject areas

  • Hepatology

Fingerprint

Dive into the research topics of 'Effect of physician-prescribed nalmefene on alcohol intake reduction in patients with alcohol-related liver disease'. Together they form a unique fingerprint.

Cite this